Navigation Links
Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
Date:11/8/2007

arter of 2008. We believe there may be more than 100,000 pancreatic MRI imaging procedures conducted in the U.S. each year that could benefit from the use of secretin.

Uridine for Bipolar Disorder

Today we reported the results from our Phase 2 clinical trial of RG2417, an oral formulation of uridine, in bipolar disorder. This was a multi-center study in which 84 patients received RG2417 or a placebo over a 6-week period. The objective of the study was to assess the safety and efficacy of RG2417 on the symptoms of bipolar depression as measured by the co-primary endpoints, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). Patients were evaluated at baseline and then weekly using these standardized tools to assess change in their symptoms. Over the six-week treatment period, the study demonstrated a statistically significant improvement in the symptoms of depression in the patients receiving RG2417 when compared to placebo on the MADRS (p=0.03) and a strong trend toward improvement on the CGI-BP-C (p=0.06). This study was conducted under a development agreement with the Stanley Medical Research Institute.

Transcription Activators for Friedreich's Ataxia

In April, we acquired the rights to intellectual property covering compounds which may have utility in treating Friedreich's ataxia. We have synthesized and evaluated more than 100 compounds for their activity and have identified several with improved potency and specificity. We are continuing to evaluate this family of compounds for activity in animal models of Friedreich's ataxia and other neurodegenerative diseases. In September, we received a $100,000 research grant from the Friedreich's Ataxia Research Alliance (FARA) to support some of the research activities. FARA is a non- profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's ataxia.

'/>"/>
SOURCE Repligen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... STOCKHOLM, SWEDEN (PRWEB) August 21, 2014 ... today that this year's conference will focus on ... be expected for research, innovation and commercialization. , ... successful ventures, SALSS combines the worlds' of business ... to a widely recognized Summit, gathering a diverse ...
(Date:8/21/2014)... News) -- In a new review of seafood safety, ... tuna due to concerns about mercury exposure. "We,re ... to shrimp as the most commonly eaten seafood in ... all tuna," Jean Halloran, director of food policy initiatives ... said in a news release from the group. ...
(Date:8/21/2014)... (HealthDay News) -- Using two types of polio vaccines ... may boost efforts to eradicate polio, a new study ... India found that giving the Salk inactivated poliovirus vaccine ... Sabin live-attenuated oral poliovirus vaccine (OPV) appeared to improve ... The findings, reported in the Aug. 22 issue of ...
(Date:8/21/2014)... 2014 The Onder Law Firm, nationally-renowned ... law, announces the launch of a new Morcellator Cancer ... morcellator surgery lawsuits for cancer claims, including ... warning and the July 2014 morcellator recall. , ... 2014 FDA warning on morcellator surgery and cancer, federal ...
(Date:8/21/2014)... 2014. Researchers have published a study examining racial ... with motor complete spinal cord injury (SCI). The ... discharge and follow-up among patients with motor complete ... August 2 by the Archives of Physical ... small but significant differences in self-care and mobility ...
Breaking Medicine News(10 mins):Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2
... Organizations, Advocates, Government Agencies, and Scientists from Academic Institutions ... ... 13 Leadership and senior staff of,twenty- seven breast ... along with experts from government agencies, scientists,from academic institutions ...
... Society of America (GSA) has chosen W. Andrew Achenbaum ... of the Donald P. Kent Award. This distinguished honor ... exemplifies the highest standards for professional leadership in gerontology ... larger society. , The award presentation will take ...
... has chosen Nancy L. Pedersen of Sweden,s Karolinska Institutet ... Contribution to Gerontology. This prize is given annually to ... a new synthesis and perspective or have yielded original ... the literature. , The award presentation will take place ...
... operated on, or the wrong transplant, study found , , TUESDAY, ... in eye surgery, say U.S. researchers who analyzed 106 cases ... the wrong site or using wrong procedure. , The ... College in New York found: , The most common ...
... Nov. 13 Green Earth Waterless Carwash, the,only Los ... products and auto detailing services, today announced an agreement,with ... month as part of,the hospital,s employee appreciation program. An ... to the hospital. "We originally signed on for ...
... - Seattle & King County and RediClinic, offers Seattle-area residents a, convenient opportunity to get ... themselves and the many lives they touch, - Vaccination ... ... between mid ...
Cached Medicine News:Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 2Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 3Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 4Health News:Eye Surgery Errors Rare But Serious 2Health News:Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 3Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 4Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 5Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 6
(Date:8/21/2014)... Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading ... announced today the appointments of Andrew ("Andy") Arno and ... of Directors. With these additions, the Asterias Board of ... independent. Andy Arno , 55, has ... He is currently Managing Director of Emerging Growth Equities, ...
(Date:8/20/2014)... , Aug. 20, 2014 The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down meth offenders and make arrests. ... Kansas blocked the sale ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
The GLU method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Lipase in human serum and plasma....
Medicine Products: